China Forges Ahead in AI Brain Implants, Bridging Trials to Real-World Use

China is aggressively pushing the boundaries of neurotechnology, with its companies leading a global race to develop and deploy artificial-intelligence powered brain-computer interfaces (BCIs). These revolutionary devices are designed to empower individuals with paralysis or neurodegenerative diseases by enabling them to move, speak, and control external devices through thought. Over the past decade, BCIs, which establish a direct link between a person's brain and an external computer or device using sensors, have shown significant promise in clinical settings. A key innovation in recent years, predominantly from firms in China and the United States, has been the integration of large language models (LLMs) into these brain devices. This fusion of AI allows scientists to decode complex brain activity with unprecedented accuracy, far surpassing the capabilities of conventional signal-processing and data-analysis technologies, as highlighted by Li Haifeng, a neuro-computing scientist. Consequently, small-scale human trials are actively underway across China, with some AI-powered brain devices slated for public sale in the near future. Leading this charge is Shanghai-based NeuroXess, which has conducted successful clinical trials. One notable trial involved a 28-year-old man with a spinal cord injury, who, fitted with a NeuroXess AI-powered brain implant, was able to control household appliances by manipulating a computer cursor with his thoughts. The implant, strategically placed on the skull with sensors on the cerebral cortex, connects to a chest-embedded data transmitter and battery. Furthermore, NeuroXess has developed an LLM that enables real-time decoding of Mandarin at an astounding rate of 300 characters per minute, exceeding the average human speaking speed. This technology successfully generated words and phrases for a 35-year-old woman with epilepsy, demonstrating its potential for restoring communication. The Chinese government is a major driving force behind this rapid progress, articulating an ambitious goal to become a global leader in BCIs by the end of the decade. Specific targets include achieving significant technical breakthroughs by 2027 and fostering the emergence of two to three world-class BCI firms. This commitment was underscored by the approval of the world's first commercial brain implant in March, signaling a clear path from research to market. However, the swift advancement of neurotechnology, particularly its combination with AI, inevitably raises critical questions regarding user data privacy and ethical oversight. Companies face scrutiny over how they will manage sensitive personal data. In response, the Chinese government has proactively developed and released ethical guidelines for BCIs in 2024. These guidelines mandate written consent from trial participants or their guardians and require all trials to undergo rigorous ethics assessments. Meicen Sun, an information scientist, notes that the Chinese public generally exhibits higher tolerance for companies accessing their data and a greater willingness to experiment with new technologies, which creates a "self-reinforcing loop" where data access fuels technological improvement and user confidence.